Free Trial

Molecular Partners (MOLN) Competitors

Molecular Partners logo
$3.59 +0.03 (+0.84%)
Closing price 10/24/2025 03:45 PM Eastern
Extended Trading
$3.58 0.00 (-0.14%)
As of 10/24/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MOLN vs. GLUE, SIGA, MLTX, ARCT, OPT, KALV, NAGE, ESPR, BCYC, and CMPX

Should you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Monte Rosa Therapeutics (GLUE), Siga Technologies (SIGA), MoonLake Immunotherapeutics (MLTX), Arcturus Therapeutics (ARCT), Opthea (OPT), KalVista Pharmaceuticals (KALV), Niagen Bioscience (NAGE), Esperion Therapeutics (ESPR), Bicycle Therapeutics (BCYC), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry.

Molecular Partners vs. Its Competitors

Monte Rosa Therapeutics (NASDAQ:GLUE) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Molecular Partners has lower revenue, but higher earnings than Monte Rosa Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$75.62M9.10-$72.70M$0.3630.94
Molecular Partners$5.65M25.66-$61.39M-$2.08-1.73

Monte Rosa Therapeutics has a net margin of 13.58% compared to Molecular Partners' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 9.95% beat Molecular Partners' return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics13.58% 9.95% 6.42%
Molecular Partners N/A -50.66%-45.13%

Monte Rosa Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Monte Rosa Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.95 beat Monte Rosa Therapeutics' score of 0.88 indicating that Molecular Partners is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monte Rosa Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Molecular Partners
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Monte Rosa Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 37.64%. Molecular Partners has a consensus target price of $8.00, suggesting a potential upside of 122.84%. Given Molecular Partners' higher probable upside, analysts plainly believe Molecular Partners is more favorable than Monte Rosa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Molecular Partners
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 6.9% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Monte Rosa Therapeutics beats Molecular Partners on 12 of the 16 factors compared between the two stocks.

Get Molecular Partners News Delivered to You Automatically

Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MOLN vs. The Competition

MetricMolecular PartnersMED IndustryMedical SectorNASDAQ Exchange
Market Cap$143.73M$3.43B$6.24B$10.65B
Dividend YieldN/A2.27%5.71%4.82%
P/E Ratio-1.7325.8530.6130.44
Price / Sales25.66514.92596.73191.77
Price / CashN/A45.5737.0161.44
Price / Book0.9010.4012.036.60
Net Income-$61.39M-$52.72M$3.32B$276.82M
7 Day Performance-5.40%2.10%1.89%2.55%
1 Month Performance-3.62%12.33%7.71%3.76%
1 Year Performance-44.68%14.14%56.33%33.04%

Molecular Partners Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MOLN
Molecular Partners
1.6555 of 5 stars
$3.59
+0.8%
$8.00
+122.8%
-40.4%$143.73M$5.65M-1.73180News Coverage
Upcoming Earnings
GLUE
Monte Rosa Therapeutics
2.4736 of 5 stars
$9.59
-2.8%
$15.33
+59.9%
+128.7%$609.57M$75.62M26.6490News Coverage
SIGA
Siga Technologies
2.1349 of 5 stars
$8.47
-0.1%
N/A+28.1%$607.22M$138.72M7.5040Positive News
MLTX
MoonLake Immunotherapeutics
2.8943 of 5 stars
$9.16
-2.0%
$36.00
+293.0%
-79.4%$600.88MN/A-3.292Trending News
ARCT
Arcturus Therapeutics
3.4575 of 5 stars
$23.16
+7.7%
$50.57
+118.4%
-40.9%$584.09M$152.31M-10.39180Trending News
Analyst Downgrade
Analyst Revision
High Trading Volume
OPT
Opthea
0.4522 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
-18.8%$583.10M$30K0.008News Coverage
Gap Up
High Trading Volume
KALV
KalVista Pharmaceuticals
3.8146 of 5 stars
$11.43
-1.0%
$26.43
+131.2%
-7.8%$583.04M$1.43M-2.90100
NAGE
Niagen Bioscience
2.2923 of 5 stars
$7.51
+4.2%
$13.42
+78.7%
N/A$575.02M$116.30M35.76120
ESPR
Esperion Therapeutics
3.7315 of 5 stars
$2.79
-1.1%
$7.00
+150.9%
+31.6%$568.58M$268.13M-5.69200
BCYC
Bicycle Therapeutics
3.4248 of 5 stars
$8.29
+1.6%
$22.22
+168.1%
-68.2%$565.54M$35.28M-2.36240Upcoming Earnings
CMPX
Compass Therapeutics
2.3999 of 5 stars
$4.10
+1.2%
$13.10
+219.5%
+125.6%$560.04M$850K-9.1120Analyst Forecast

Related Companies and Tools


This page (NASDAQ:MOLN) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners